Tecfidera

What is it?

Composition

Active ingredient: dimethyl fumarate. Tecfidera is supplied as delayed-release capsules for oral use, designed to release the medicine in the gastrointestinal tract rather than immediately in the stomach.

How to use?

Tecfidera is used for the treatment of relapsing forms of multiple sclerosis in adults. It is taken as a long-term disease-modifying therapy to reduce relapse frequency and help limit new inflammatory disease activity. Treatment is prescribed and monitored by a clinician with periodic blood tests.

How does it work?

• Route/form: oral, delayed-release capsule
• Starting dose: 120 mg twice daily for 7 days
• Maintenance dose: 240 mg twice daily starting on day 8 and continued long term as prescribed
• Timing with meals: take with or without food; taking with food may reduce flushing and stomach upset
• How to take: swallow capsules whole; do not crush, chew, or open
• Missed dose: take the next dose at the usual time; do not take two doses at once

Indications

Tecfidera is used to treat Multiple Sclerosis (MS), and it is used for relapsing forms where inflammatory attacks can cause new or worsening neurological symptoms.

Comparison

Tecfidera is one of several oral disease-modifying therapies used for relapsing MS. Two commonly discussed alternatives in the same decision space are fingolimod (Gilenya, sometimes written as Gilenya®) and teriflunomide; leflunomide is related pharmacologically to teriflunomide (teriflunomide is the active metabolite of leflunomide).

These options differ in mechanism, monitoring needs, and which risks dominate the conversation. Fingolimod acts on sphingosine-1-phosphate receptors to reduce lymphocyte egress from lymph nodes, and it brings specific cardiac and eye-related monitoring considerations for some patients. Teriflunomide reduces de novo pyrimidine synthesis in rapidly dividing immune cells, and it carries strong pregnancy-related precautions, plus liver monitoring.

Choice is individual. MRI activity, relapse pattern, comorbidities, and family planning often decide more than “which is strongest.”

Contraindications

• Known hypersensitivity to dimethyl fumarate or capsule components
• Serious active infection where immune suppression would be unsafe
• History of severe, persistent low white blood cell counts unless an MS specialist has a clear monitoring plan

Not recommended for

• If you are allergic to dimethyl fumarate or any ingredient in the capsule
• If you currently have a serious infection and your immune system should not be suppressed
• If you have had very low white blood cell counts for a long time and do not have a specialist monitoring plan

Side effects

Side effects with Tecfidera® cluster into two buckets: common tolerability issues and rare but serious safety events.

Common side effects many patients notice early

• Flushing (warmth, redness, itching, tingling), often in the first weeks
• Gastrointestinal effects: nausea, abdominal pain, diarrhoea, indigestion
• Reduced appetite
• Rash or itching
• Changes in liver blood tests can occur

Some days are uncomfortable. Many patients still stay on it.

Less common but serious risks

• Lymphopenia (low lymphocyte count): Tecfidera can lower white blood cells over time, which raises infection risk and is one reason routine blood monitoring is built into MS care pathways.
• Serious infections, including PML: Progressive multifocal leukoencephalopathy (PML) is a rare brain infection linked to JC virus reactivation in people with impaired immune surveillance; it has been reported with dimethyl fumarate in the setting of prolonged or severe lymphopenia ^[2].
• Liver injury: symptoms such as dark urine, severe fatigue, or yellowing of the eyes need urgent medical assessment.

Here’s a practical red-flag pattern clinicians listen for: new, progressive neurological changes that don’t feel like your prior relapses (new personality change, worsening coordination, persistent one-sided weakness, or new vision problems). PML can look “odd” compared with typical relapse patterns.

Common mistakes

People make the same errors with Tecfidera, and they are avoidable.

• Taking capsules on an empty stomach and then assuming the medicine is intolerable. Food timing can change flushing and nausea a lot.
• Restarting at the full prescribed dose after a break. After missed weeks, many prescribers re-titrate to reduce flushing and GI effects; restarting abruptly is a common reason patients quit.
• Ignoring recurring infections (mouth ulcers, frequent colds, shingles-like rash) while continuing treatment without checking blood counts.
• Using antacids or anti-diarrhoeals randomly without a plan; some people mask a problem that needs evaluation, like dehydration or persistent GI inflammation.
• Assuming any neurological change is an MS relapse. New patterns need assessment, since infections, fever, and rare events like PML can mimic relapse symptoms.

Doctor opinions

Neurologists tend to frame Tecfidera as a balance between convenience and monitoring. The convenience is real: oral dosing, no infusion appointments, and a long track record in relapsing MS care. The trade-off is lab follow-up, because the main preventable safety issue is unrecognised lymphopenia that persists.

One more real-world observation: people who already have sensitive digestion (IBS-like symptoms, reflux, frequent gastritis) report more early drop-off unless proactive food strategies are used.

Frequently asked questions

What does PML mean with Tecfidera?

PML is a brain infection caused by JC virus reactivation in the setting of reduced immune surveillance, so PML is a brain infection in clinical terms. In 2026 safety communications, regulators continue to link most dimethyl fumarate–associated PML cases to prolonged, significant lymphopenia, which is why routine blood counts are central to risk reduction. Any new, progressive neurological symptoms that feel different from prior relapses need urgent assessment.

How long does Tecfidera take to start working?

Tecfidera does not “work” in a way you can feel immediately, since it targets relapse biology and new lesion formation rather than giving fast symptom relief. In 2026, clinicians often assess benefit over months using relapse rate, MRI activity, and disability measures, not day-to-day sensations. This measurement approach matches how the WHO frames MS care: prevention of inflammatory activity and long-term disability risk, tracked with objective outcomes ^[5].

Does Tecfidera have a 240 mg strength?

Tecfidera has strength 240mg in standard maintenance dosing in many prescribing protocols, after an initial titration phase. Your prescriber selects the schedule to reduce early side effects, then aims for steady exposure to reduce relapse activity. In 2026, the EMA continues to describe a titration-to-maintenance approach for dimethyl fumarate as part of safe initiation and tolerability management.

Who manufactures Tecfidera?

Tecfidera is manufactured by BIOGEN IDEC UK LIMITED as a listed manufacturer entity in many regulatory and product-information contexts. Manufacturing details matter clinically mainly for pharmacovigilance traceability and consistent formulation standards. In 2026, prescribers focus more on your lab trends and relapse control than on the corporate details, but the manufacturer name is still part of formal medicine identification in records.

Can Tecfidera be taken with other MS treatments?

Combination use with other disease-modifying MS therapies is not routine and is often avoided because overlapping immune effects can raise infection risk. In 2026 clinical practice, neurologists usually sequence therapies rather than stack them, unless a specialist team has a defined rationale and monitoring plan. Safety guidance used by regulators continues to prioritise minimising additive immunosuppression when alternatives exist.

Do you offer anonymous delivery?

Front view

Side view

Back view

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.